Aldevron News / Aldevron

Aldevron Acquires Nature Technology Corporation

Acquisition combines Aldevron's leadership in GMP manufacturing with Nature Tech's portfolio of proprietary technologies.

Aldevron has acquired Nature Technology Corporation (NTC), a developer of innovative and proprietary plasmid constructs and manufacturing solutions that are used in the field of cell and gene therapy. NTC's nucleic acid-based technologies include NanoplasmidTM, a proprietary vector construct that improves the safety and performance of plasmids and biologics. Aldevron and NTC have complementary service offerings and pairing Aldevron's world-class manufacturing capabilities with NTC's innovative solutions will further support our clients and the patients they serve.

For more information about Nature Technology Corporation's full suite of offerings, visit www.natx.com

To get started now, complete the form, and a client relations representative will be in contact very soon.

Read More

Aldevron Now Offering Its pALD-Help Plasmid for Viral Vector Production in GMP-Source® Quality Level

Aldevron is now offering its pALD-HELP, an off-the-shelf product supporting AAV viral vector manufacturing, in its proprietary GMP-Source® (GMP-S) quality level. The plasmid is royalty-free for all applications in support of pre-clinical activities through clinical development.

The addition of this widely used plasmid expands Aldevron’s suite of ready-to-use and royalty-free constructs in support of making AAV via triple transfection, including its rep/cap plasmids 2, 5 and 6. The pALD-AAV6 plasmid is also available at the GMP-Source quality level.

“We launched this Ad helper plasmid in Research Grade as an inventory product earlier this fall and it was very well received,” said Michelle Berg, President, GMP Nucleic Acids for Aldevron. “Offering pALD-HELP in our GMP-Source quality level is another way we can support our clients in their efforts to get potential therapies to their patients sooner. Aldevron continuously looks for ways to improve our service to clients and expanding our portfolio of standardized products across quality levels ensures they have the quality products they need, when they need them.”

Aldevron has more than 23 years of experience manufacturing high-quality custom products that are used by companies around the world, along with a catalog of products that provide a consistent, reliable option to help clients meet deadlines. In addition to the AAV construct suite, Aldevron’s inventory product lines also include lentivirus plasmids, IVT enzymes, and a variety of CRISPR nucleases.

Read More

In the News: Isolere Bio Enters into Agreement with Aldevron to Develop a Scalable Manufacturing Process for IsoTag Reagents

Isolere  Bio, a biotech firm working to develop a low-cost, high throughput, and scalable purification platform, has entered into an agreement with Aldevron , a leading research to GMP biomanufacturer of plasmid DNA, mRNA, and proteins, to develop a low-cost manufacturing strategy for its IsoTag™ reagents, that is able to easily scale up to meet demand for an industry that is seeing tremendous growth and bottleneck pressures.
Read More

Aldevron Now Offering pALD-HELP Plasmids for Viral Vector Production

Aldevron announced today it is now offering pALD-HELP to support AAV viral vector manufacturing. This additional Ad helper plasmid is immediately available in Research Grade, with the GMP-Source® product expected to become available in Q4 2021. The plasmid is royalty-free for all applications in support of pre-clinical activities through clinical development and commercial production.
Read More

In the News: AavantiBio and Aldevron Announce Strategic Partnership to Develop Next Generation Gene Therapies for Rare Genetic Diseases

AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, and Aldevron, a global leader in the custom development and manufacture of plasmid DNA, proteins and mRNA for the biotech industry, today announced a long-term strategic partnership for the supply of plasmid DNA that will enable AavantiBio to advance its platform of innovative gene transfer therapies.
Read More

In the News: Aruvant Partners with Aldevron to Provide Key Plasmid Raw Materials Used to Manufacture Pipeline Products

Aruvant Sciences, a private company focused on developing gene therapies for rare diseases, and Aldevron, the leading provider of high-quality plasmid DNA, mRNA and recombinant proteins necessary for vaccines, gene and cell therapy, gene editing and diagnostic applications, announced today that Aldevron will support the development of ARU-1801, Aruvant’s one-time investigational gene therapy for sickle cell disease (SCD), and ARU-2801, a one-time investigational gene therapy for hypophosphatasia (HPP). Aldevron will provide good manufacturing practice (GMP)-grade plasmid for Aruvant’s upcoming ARU-1801 pivotal trial.

Read More

In the News: Moderna and Aldevron Announce Expanded Partnership for mRNA Vaccine and Therapeutic Pipeline

Moderna, Inc. (Nasdaq:MRNA), and Aldevron have announced their expanded collaboration in support of the Moderna COVID-19 Vaccine and additional programs in Moderna’s clinical development pipeline. Specifically, Aldevron will supply plasmid DNA to serve as the genetic template for generating the COVID-19 mRNA vaccine and other investigational programs in Moderna’s pipeline.

Read More